· Primary or active Subfoveal CNV from AMD- predominantly classic, minimally classic and occult are acceptable.  Minimally classic and occult must have evidence of recent progression

· Total area of CNV must be ≥50% of total lesion area

· Total lesion area must have the GLD ≤5400 μm

· Va approx. 20/40 – 20/320 Snellen (73-24 BCVA letters)

· For additional information- see study coordinator

· Prior PDT, Subfoveal focal laser, submacular surgery, TTT, external-beam radiation

· Prior tx with Macugen, Lucentis, Avastin or other anti-angiogenic agents like Ruboxistaurin, Anecortave Acetate, Squalamine, SIRNA, VEGF-Trap etc.

· Fellow eye treatment with those meds listed above is permitted if administered > 30 days before screening.

· Presence of fibrosis, heme, PED or other hypo fluorescent lesions obscuring >50% of the CNV

· Uncontrolled glaucoma in SE (IOP ≥25 despite tx with 2 or more meds)

· Hx of intraocular surgery within 60 days prior to screening (except for uncomplicated CE)

· Hx of YAG capsulotomy in the SE within 30 days prior to screening

· Presence of angioid streaks, presumed ocular histo, pathologic myopia (>8 D or evidence of posterior segment abnormalities assoc. with pathologic myopia) or any other reason for CNV

· Tear or rip of RPE

· Active or hx of ocular inflammation or infection in the SE within the last 30 days